Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study

D'Agostino M, Schett G, Lopez-Rdz A, Senolt L, Maldonado-Cocco J, Burgos-Vargas R, Naredo E, Carron P, Boers M, Duggan AM, Goyanka P, Gaillez C (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Universidad de Buenos Aires (UBA) / University of Buenos Aires

Argentina (AR) Vrije Universiteit Amsterdam (VU) / University Amsterdam

Netherlands (NL) Dermatológico country

Mexico (MX) Hospital General de México

Mexico (MX) Novartis AG

Switzerland (CH) Novartis Ireland Limited

Ireland (IE) Fundación Jiménez Díaz

Spain (ES) Univerzita Karlova v Praze / Charles University in Prague

Czech Republic (CZ) University Hospital Ghent

Belgium (BE) Versailles Saint-Quentin-en-Yvelines University / Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)

France (FR)

How to cite

APA:

D'Agostino, M., Schett, G., Lopez-Rdz, A., Senolt, L., Maldonado-Cocco, J., Burgos-Vargas, R.,... Gaillez, C. (2020). Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.

MLA:

D'Agostino, Maria, et al. "Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2020.

BibTeX: Download